{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:01:35Z","timestamp":1771678895306,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.antiviral.2014.01.008","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T20:05:46Z","timestamp":1390507546000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease"],"prefix":"10.1016","volume":"104","author":[{"given":"Young-Man","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Suk","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Ju","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Eun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Na","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Moo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.008_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhin.2012.05.011","article-title":"Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit","volume":"81","author":"Alan","year":"2012","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.antiviral.2014.01.008_b0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(00)00213-9","article-title":"Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice","volume":"19","author":"Boelen","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.01.008_b0015","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4049\/jimmunol.180.4.2376","article-title":"IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease","volume":"180","author":"Castilow","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0020","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1128\/JVI.01949-07","article-title":"Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus","volume":"82","author":"Castilow","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol. Res."},{"key":"10.1016\/j.antiviral.2014.01.008_b0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/320714","article-title":"Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs","volume":"183","author":"Chatterjee","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.008_b0035","doi-asserted-by":"crossref","first-page":"8446","DOI":"10.1128\/JVI.78.16.8446-8454.2004","article-title":"Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein","volume":"78","author":"Elliott","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/CDLI.3.3.280-286.1996","article-title":"Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies","volume":"3","author":"Gimenez","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0045","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.antiviral.2014.01.008_b0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2014.01.008_b0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14712598.2012.665048","article-title":"Palivizumab and emerging therapies for respiratory syncytial virus","volume":"12","author":"Hoopes","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.antiviral.2014.01.008_b0060","doi-asserted-by":"crossref","first-page":"e36812","DOI":"10.1371\/journal.pone.0036812","article-title":"Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice","volume":"7","author":"Kamphuis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.01.008_b0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/viro.2000.0186","article-title":"Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate","volume":"269","author":"Li","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.01.008_b0080","doi-asserted-by":"crossref","first-page":"13710","DOI":"10.1128\/JVI.01351-07","article-title":"Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats","volume":"81","author":"Mok","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0085","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.01709-09","article-title":"Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB\/c mice, with no evidence of immunopathology","volume":"84","author":"Murawski","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0090","doi-asserted-by":"crossref","first-page":"e8088","DOI":"10.1371\/journal.pone.0008088","article-title":"The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya","volume":"4","author":"Ochola","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.01.008_b0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00019053-200422050-00001","article-title":"Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases","volume":"22","author":"Paramore","year":"2004","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.antiviral.2014.01.008_b0100","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1099\/0022-1317-82-12-2881","article-title":"Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine","volume":"82","author":"Prince","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/JVI.57.3.721-728.1986","article-title":"Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus","volume":"57","author":"Prince","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/infdis\/jir474","article-title":"Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice","volume":"204","author":"Quan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.008_b0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0b013e318235455b","article-title":"Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria","volume":"31","author":"Resch","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2014.01.008_b0120","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.0.CO;2-L","article-title":"Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice","volume":"28","author":"Siegrist","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2010.05.034","article-title":"Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles","volume":"405","author":"Song","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.01.008_b0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.01.008_b0135","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1016\/S0264-410X(03)00336-0","article-title":"Transfer of antibody via mother\u2019s milk","volume":"21","author":"Van de Perre","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2014.01.008_b0140","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.71.9.6935-6939.1997","article-title":"Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB\/c mice immunized with formalin-inactivated RSV","volume":"71","author":"Waris","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0145","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/JVI.70.5.2852-2860.1996","article-title":"Respiratory synctial virus infection in BALB\/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern","volume":"70","author":"Waris","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.008_b0150","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.4049\/jimmunol.1100764","article-title":"Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection","volume":"187","author":"Weiss","year":"2011","journal-title":"J. Immunol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T14:48:59Z","timestamp":1597416539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":30,"alternative-id":["S0166354214000205"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}